Duration of anticoagulant therapy and VTE recurrence in patients with cancer

PURPOSE: Anticoagulant therapy for at least 3–6 months is currently recommended for treatment of venous thromboembolism (VTE) in patients with cancer, but the optimal duration of treatment is unknown. This study examines the association between the duration of anticoagulation treatment and VTE recur...

Descripción completa

Detalles Bibliográficos
Autores principales: Khorana, Alok A., McCrae, Keith R., Milentijevic, Dejan, Fortier, Jonathan, Nelson, Winnie W., Laliberté, François, Crivera, Concetta, Lefebvre, Patrick, Schein, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726708/
https://www.ncbi.nlm.nih.gov/pubmed/30734088
http://dx.doi.org/10.1007/s00520-019-4661-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726708/
https://www.ncbi.nlm.nih.gov/pubmed/30734088
http://dx.doi.org/10.1007/s00520-019-4661-3

Ejemplares similares